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Abstract A large body of work has proved that transcription by
RNA polymerase II and pre-mRNA processing are coordinated
events within the cell nucleus. Capping, splicing and polyadeny-
lation occur while transcription proceeds, suggesting that RNA
polymerase II plays a role in the regulation of these events. The
presence and degree of phosphorylation of the carboxy-terminal
domain of RNA polymerase II large subunit is important for
functioning of the capping enzymes, the assembly of spliceosomes
and the binding of the cleavage/polyadenylation complex.
Nuclear architecture and gene promoter structure have also been
shown to play key roles in coupling between transcription and
splicing. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Eukaryotic gene expression involves several steps that start
with transcription. Three RNA polymerases (RNA pol) are in
charge of transcribing the genes in the nucleus: RNA pol I
transcribes most of the ribosomal RNAs (28S, 18S and 5.8S
rRNAs); RNA pol II transcribes messenger RNAs (mRNAs),
as well as some small nuclear RNAs (snRNAs); and RNA pol
III synthesizes 5S rRNA, transfer RNAs (tRNAs) and some
other snRNAs.
Many of these RNAs undergo modi¢cations or processing
that determine speci¢c features, such as their location, stabil-
ity, or interaction with macromolecular complexes. In the past
few years, transcription and processing of RNAs have been
studied thoroughly so we now have a large body of informa-
tion about both the protein machineries involved and the
sequences required on the DNA template and on the tran-
scripts. However, most of this knowledge comes from in vitro
experiments in which each step of RNA synthesis was studied
in isolation in the test tube, thus leading to the view that these
steps were independent of each other and took place subse-
quently. Evidence accumulated in recent years has proved this
concept wrong as it shows that several of the steps involved in
gene expression are coordinated within the cell nucleus. In
fact, this coordination in some cases requires the interaction
of genes and transcripts with protein complexes of such large
size that they can be distinguished by light microscopy.
In this review we will focus on the coupling of transcription
and RNA processing of mRNAs by RNA pol II. We encour-
age the reading of other recent reviews in the ¢eld [1^3].
2. RNA pol II plays a key role in coordination between
transcription and processing
Transcripts synthesized by RNA pol II undergo speci¢c and
extensive processing before being transported to the cyto-
plasm. Capping at the 5P end minimizes mRNA degradation
and most importantly permits its interaction with the ribo-
somes in the cytoplasm. The 3P end is completed by the addi-
tion of a polyadenosine monophosphate tail, resulting in in-
creased mRNA stability. Transcribed intervening sequences,
called introns, are removed. Far from being unrelated events
that take place sequentially, transcription and processing are
coordinated in both time and space. In many cases these
modi¢cations take place as transcription proceeds. This led
to the idea that RNA pol II itself might be responsible for
coordinating all the steps required for mature mRNA biogen-
esis.
RNA pol II is a multimeric protein. The enzymatic activity
is located in its largest subunit, characterized by a carboxy-
terminal domain (CTD) composed of 52 repeats of the heptad
consensus peptide YSPTSPS in mammals. The fact that this
domain is a unique feature of this protein, together with the
presence of serines and threonines in the repeat that could be
candidates for phosphorylation, suggested that the CTD and
its putative phosphorylated residues could be the signals used
by the protein machineries involved in mRNA synthesis and
processing to contact the right polymerase [4]. In fact, RNA
pol II is phosphorylated in vivo and can be isolated from
mammals and £ies in a hyperphosphorylated form (RNA
pol IIO) or a hypophosphorylated form (RNA pol IIA) dis-
tinguishable by speci¢c antibodies [5]. Immunoprecipitation of
RNA pol II transcribing the Drosophila melanogaster hsp70
inducible gene showed that whereas elongating complexes are
composed of RNA pol IIO, complexes that paused 20^40
bases downstream of the transcription start site are rich in
RNA pol IIA [6]. The cdk7-cyclin H component of TFIIH
in mammals and Kin28 in yeast [7] phosphorylate the CTD in
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the preinitiation complex stimulating transcription by RNA
pol II. P-TEFb in mammals [8], and in yeast SRB10, SRB11
[9] and CTK1 [10] also function as CTD kinases. The role of
each kinase in transcription remains unclear. It has been pro-
posed that di¡erent promoters could recruit di¡erent kinases
[5]. This could result in varying elongation e⁄ciencies that
could in turn a¡ect splicing or polyadenylation. A phospha-
tase called FCP1 has been described to act as an inhibitor of
early elongating RNA pol II [11,12], supporting the view that
cycles of phosphorylation/dephosphorylation are involved in
transcription regulation at the level of elongation.
3. Capping and transcription are tightly coupled
Capping is the best described example of a pre-mRNA pro-
cessing reaction coupled to transcription. After RNA pol II
transcribes the ¢rst 25^30 nucleotides, the capping enzymes
proceed to remove the Q-phosphate from the ¢rst nucleotide of
the RNA, transfer GMP from GTP to this latter to form the
GpppN, which is later methylated at the N7 position of the
guanine. These activities are performed by two proteins in
mammals: a bifunctional polypeptide with a triphosphatase
domain in its amino-terminus and a guanylyltransferase do-
main in its carboxy-terminus, and a separate methyltransfer-
ase. In yeast, the triphosphatase (Cet1) and the guanylyltrans-
ferase (Ceg1) are separate subunits while a third polypeptide,
called Abd1, methylates the guanine. The mammalian capping
enzyme binds RNA pol IIO but not RNA pol IIA [13,14].
This interaction is sensitive to the CTD phosphorylation sta-
tus as demonstrated by in vitro binding of the guanylyltrans-
ferase domain to CTD peptides phosphorylated at Ser5 (but
not at Ser2) [15]. As a consequence of this interaction the
a⁄nity of guanylyltransferase for GTP increases two-fold.
Moreover, in vivo functional studies performed in HeLa cells
have shown that upon inhibition of the endogenous RNA pol
II by the addition of K-amanitin and simultaneous transfec-
tion with a plasmid expressing an K-amanitin-resistant, CTD-
less version of the enzyme, the cells are unable to cap an
mRNA encoded in a reporter plasmid [16].
In yeast, direct contacts of Ceg1, Cet1 and Abd1 with the
CTD were demonstrated in vivo. Surprisingly, Ceg1 is re-
leased early in elongation while Abd1 travels with the poly-
merase as far as the 3P end of the gene [17]. Moreover, these
contacts are restricted to genes that are being actively tran-
scribed and require a functional Kin28 (but not CTK1 or
SRB10) that phosphorylates Ser5 in the CTD. It seems then
that CTD phosphorylation at this position is critical for
mRNA capping. These ¢ndings are consistent with the pre-
vious ¢nding that a viable mutant carrying a shortened CTD
combined with a viable mutation of the capping enzyme leads
to death [18].
4. Nuclear structure and the coordination between transcription
and splicing
Most metazoan RNA pol II genes include introns that are
eliminated from the pre-mRNA through splicing. The splice-
osome, composed of small nuclear ribonucleoproteins
(snRNP) and non-snRNP proteins, interacts with sequences
in the RNA molecule helped by members of a family of argi-
nine/serine-rich proteins (SR proteins). It was initially as-
sumed that mRNA molecules were spliced only after being
completely synthesized and released from the DNA template.
However, examination of expression of the rat ¢bronectin
(FN) gene employing £uorescent probes showed that the tran-
scripts do not di¡use freely in the nucleoplasm from the site of
transcription but form one elongated ‘track’ per allele. Inter-
estingly, tracks are constituted of unspliced mRNA in the
proximity of the gene and of mature mRNA towards the
more distal parts [19]. Cytological examination of insect genes
caught in active transcription showed that some introns are
excised as the mRNA is being synthesized [20,21]. The CTD
seems to play a central role in linking mRNA synthesis and
splicing machineries. Antibodies directed against RNA pol II
[22] or the CTD co-immunoprecipitate SR proteins and inhib-
it splicing both in vitro and in vivo [23,24]. Moreover, the
phosphorylated form of CTD stimulates the early steps of
spliceosome assembly thereby stimulating splicing while the
hypophosphorylated form inhibits the formation of these
complexes [25]. The CTD seems to accomplish this by bridg-
ing the splicing factors bound to the 3P and 5P splice sites at
the ends of each exon [26], consistent with the mechanism of
exon de¢nition of splicing [27]. The role of CTD in splicing is
so signi¢cant that transcripts generated by truncated versions
of RNA pol II lacking the CTD cannot be spliced in vivo [16].
Studies on nuclear architecture also reveal coupling of tran-
scription and splicing (for recent reviews see [28,29]). The
nucleus presents several domains [30]. Among them, splicing
factor compartments (SFCs, formerly called speckles [31,32]),
which are present at 20^50 per cell, have been shown to asso-
ciate with transcribing genes by means of live cell microscopy
[33]. While this dynamic interaction is inhibited by K-amanitin
it remains controversial whether it is intron-dependent [34] or
-independent [35].
Coupling between transcription and splicing is not limited
to just a temporal or spatial coincidence of the corresponding
machineries. Our laboratory has shown that the structure of
the promoter regulating the expression of a gene can a¡ect
splicing. Human cell lines were transiently transfected with a
series of human K-globin/FN minigenes that include the alter-
natively spliced EDI exon of FN but di¡er in the promoter
driving their expression. When the FN promoter included
point mutations that had been previously shown to a¡ect
the recruiting of speci¢c transcription factors [36] the ratio
between the two alternatively spliced forms (EDI+/EDI3)
was much higher than the one obtained from expression
from the wild type FN promoter [37]. Furthermore, a variant
of the plasmid carrying the human K-globin promoter ex-
pressed a dramatically lower proportion of EDI. Moreover,
the promoter a¡ected the responsiveness of this alternative
splicing to the activation by the SR proteins SF2/ASF and
9G8 [38]. As these splicing factors require the presence of an
intact splicing enhancer on the alternative exon in order to
stimulate EDI inclusion, it was suggested that the transcrip-
tion machinery modulates their recruitment to the splicing
enhancer. A possible mechanism that would ¢t in these results
is that the promoter itself is somehow responsible for recruit-
ing these splicing factors to the site of transcription, possibly
through transcription factors that bind the promoter or the
transcriptional enhancers. The ¢nding that p52, a transcrip-
tional coactivator, directly interacts with SF2/ASF stimulating
pre-mRNA splicing [39] is consistent with this model. Fur-
thermore, some proteins could display a dual function, acting
in both processes as is the case of a transcriptional activator
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of human papilloma virus [40] or the thermogenic coactivator
PGC-1 [41]. Alternatively, the RNA polymerase could be re-
sponsible for recruiting these proteins, perhaps through its
CTD. The role of the promoter in this case could be to a¡ect
the extent of CTD phosphorylation which could in turn mod-
ify the ability of the CTD to interact with SR proteins [38].
5. Polyadenylation and transcription are interdependent events
With the exception of histone mRNAs, a polyadenosine
monophosphate tail is added at the 3P end of all eukaryotic
messengers, resulting in increased RNA stability and also in
improved translation. In mammals the cleavage speci¢city
polyadenylation factor (CSPF) recognizes the consensus se-
quence AAUAAA (poly(A) signal), and the cleavage stimula-
tion factor some U- or GU-rich elements located downstream.
Although the cleavage reaction itself takes place some 10^30
nucleotides downstream of the poly(A) signal and requires the
presence of two other proteins (CF Im and CF IIm), RNA pol
II does not stop transcription at this point but continues
elongating the RNA for up to 1000 nucleotides. The poly(A)
tail is then added by poly(A) polymerase with the assistance
of poly(A) binding protein. It remains to be established which
of the four proteins involved in cleavage cuts the mRNA, and
more importantly, which are the signals for transcription stop
in eukaryotes.
RNA pol II plays a key role in polyadenylation. Three of
the four subunits that compose CSPF are actually part of
TFIID (a basal transcription factor) and are transferred to
the RNA pol II after initiation [42]. Immunoprecipitation of
these factors with antibodies directed against the CTD con-
¢rms that this machinery contacts the CTD, as in the case of
the capping reaction. Again, polyadenylation is impaired in
HeLa cells in which the only active RNA pol II has a trun-
cated CTD [16]. Then, we have to imagine that the transcrib-
ing RNA pol II carries at least part of the cleavage/polyade-
nylation machinery along the transcribing gene. It seems that
its role is more than just transporting these proteins to the
poly(A) signal, as both RNA pol II and the CTD alone were
shown to stimulate polyadenylation in vitro, in a transcrip-
tion-free assay [43]. Coupling between transcription and poly-
adenylation appears to be conserved from yeast to human as
illustrated by the recent ¢nding that phosphorylated CTD
binds to a cleavage complex called CF1A in yeast [44].
6. Transcription termination and 3P end mRNA processing
cannot be resolved
Termination of transcription requires a functional polyade-
nylation site [45,46]. Electron micrographs of DNA:pro-
tein:RNA complexes isolated from Xenopus laevis oocytes in-
jected with plasmids expressing pre-mRNAs that di¡er in the
strength of their poly(A) signals revealed that the length of the
nascent transcripts is constant when the poly(A) signal is
strong, whereas a mutated signal correlates with much longer
mRNAs that result from several rounds of transcription of the
circular template [47].
Extensive mutation analysis made it possible to conclude
that, besides a functional poly(A) signal, termination requires
a functional acceptor site in the last intron [48]. The timing of
the events at the 3P end of the transcript also seems to be
important as demonstrated by coupled polyadenylation^tran-
scription studies in vitro. The presence of physiological paus-
ing elements downstream of the poly(A) signal, followed by
arti¢cial ‘roadblocks’, activates polyadenylation [49]. This
pausing of the enzyme might help its interactions with the
Fig. 1. Involvement of RNA pol II in di¡erent steps of pre-mRNA processing. TF: transcription factors. Small circles represent proteins
involved in pre-mRNA processing that interact with RNA pol II, participating in capping (red), splicing (blue) or cleavage/polyadenylation
(yellow) mechanisms. Yellow squares represent factors involved in cleavage/polyadenylation which do not interact with RNA pol II.
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factors engaged in 3P processing, including splicing of the last
intron (Fig. 1).
7. Perspectives
The study of the molecular bases of pre-mRNA processing
and, in particular, of alternative splicing regulation becomes
especially relevant in the post-genome era. The identi¢cation
of all human genes will be insu⁄cient to understand cell-spe-
ci¢c patterns of gene expression since it is estimated that the
30 000 genes in the human genome could produce several
hundred thousand di¡erent proteins. The existence of a supra-
molecular compartmentalization in the mammalian cell nu-
cleus and the discovery of functional and structural coordina-
tion between transcription and pre-mRNA processing
establish a new conceptual frame to investigate the control
of gene expression. The evidence discussed here implies that
coupling between transcription and processing can be quite
complex, comprising contacts between RNA pol II, cleav-
age/polyadenylation and splicing machineries. It has not
been studied so far how many of the repeats in the CTD
and which of them need to be phosphorylated for the cou-
pling between transcription and processing. Perhaps only the
overall quantity of phosphorylated residues (namely the ex-
tent of negative charge of the CTD) is what counts, or per-
haps the phosphorylation of only some of the repeats is cru-
cial. It may well be the case that di¡erent processing
machineries require di¡erent ‘formats’ of the CTD. On the
other hand, the physiological roles of the modulation of splic-
ing by promoter structure and changes in nuclear architecture
remain to be determined.
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